Indicators
Indicators
Value
Direction
MACD(12,26,9)
-0.014
Neutral
RSI(14)
44.062
Neutral
STOCH(KDJ)(9,3,3)
38.405
Sell
ATR(14)
0.069
High Vlolatility
CCI(14)
-164.098
Sell
Williams %R
68.782
Sell
TRIX(12,20)
0.267
Sell
StochRSI(14)
0.000
Oversold
CASI Pharmaceuticals Inc
CASI0.925USD
-0.025-2.66%
Close 02/06, 16:00（ET）Quotes delayed by 15 min
14.33MMarket Cap
LossP/E TTM
TradingKey Stock Score
Overall Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Peer Comparison
TradingKey Stock Score of CASI Pharmaceuticals Inc
Currency: USD Updated: 2026-02-06Key Insights
CASI Pharmaceuticals Inc's fundamentals are relatively very healthy, with an industry-leading ESG disclosure.and its growth potential is high.Its valuation is considered fairly valued, ranking 91 out of 159 in the Pharmaceuticals industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 4.00.In the medium term, the stock price is expected to trend down.Despite a very weak market performance over the past month, the company shows strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
CASI Pharmaceuticals Inc's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Media Coverage
Last 24 hours
Coverage Level
Very Low
Very High
Neutral
CASI Pharmaceuticals Inc Highlights
StrengthsRisks
CASI Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on developing and commercializing therapeutics and pharmaceutical products in China, the United States, and throughout the world. The Company is focused on acquiring, developing, and commercializing products that augment its hematology oncology therapeutic focus as well as other areas of unmet medical need. Its commercial product, EVOMELA, is an intravenous formulation of melphalan commercialized by Acrotech in the multiple myeloma treatment setting in the United States. Its pipeline products include CNCT19 (CD19 CAR-T), BI-1206 (anti- FcYRIIB antibody), CB-5339 (VCP/p97 inhibitor), CID-103 (Anti-CD38 Mab), Thiotepa, and Octreotide LAI. The Company’s Food and Drug Administration (FDA)-approved generic products for the China market include Entecavir tablets, Tenofovir disoproxil fumarate (TDF) tablets, Cilostazol tablets-50mg, Cilostazol tablets-100mg, Ondansetron HCL tablets, and Tizanidine tablets.
Growing
The company is in a growing phase, with the latest annual income totaling USD 28.54M.
Overvalued
The company’s latest PE is -0.31, at a high 3-year percentile range.
Held by James Simons
Star Investor James Simons holds 43.90K shares of this stock.
Higher Market Activity
The company has more investor interest, with a 20-day turnover ratio of 12.46.
Analyst Rating
Based on
1
analysts
Buy
Current Rating
4.000
Target Price
+321.05%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Financial Health
Currency: USD Updated: 2026-02-06The current financial score of CASI Pharmaceuticals Inc is 7.18, ranking 127 out of 159 in the Pharmaceuticals industry. Its financial status is robust, and its operating efficiency is average. Its latest quarterly revenue reached 3.08M, representing a year-over-year decrease of 60.54%, while its net profit experienced a year-over-year decrease of 29.64%.
Score
Financials
10.00
Key Metrics
Cash and cash equivalents
Total assets
Total liabilities
Free cash flow
Relevant data have not been disclosed by the company yet.
Quality of Earnings
6.30
Operational Efficiency
6.54
Growth Potential
6.05
Shareholder Returns
7.03
CASI Pharmaceuticals Inc's Company Valuation
Currency: USD Updated: 2026-02-06The current valuation score of CASI Pharmaceuticals Inc is 8.80, ranking 7 out of 159 in the Pharmaceuticals industry. Its current P/E ratio is -0.31, which is -18.54% below the recent high of -0.25 and -1171.69% above the recent low of -3.89.
Score
Valuation Dimensions
P/E
P/B
P/S
P/CF
Industry Ranking 91/159
Relevant data have not been disclosed by the company yet.
Earnings Forecast
Currency: USD Updated: 2026-02-06The current earnings forecast score of CASI Pharmaceuticals Inc is 8.00, ranking 57 out of 159 in the Pharmaceuticals industry. The average price target is 4.00, with a high of 4.00 and a low of 4.00.
Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Analyst Rating
Based on
1
analysts
Buy
Current Rating
4.000
Target Price
+321.05%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell
Peer Comparison
173
Total
6
Median
8
Average
Company name
Ratings
Analysts
CASI Pharmaceuticals Inc
CASI
1
Biogen Inc
BIIB
36
Amgen Inc
AMGN
35
Eli Lilly and Co
LLY
33
Vertex Pharmaceuticals Inc
VRTX
33
Gilead Sciences Inc
GILD
31
1
2
3
...
35
Financial Forecasting
EPS
Revenue
Net Profit
EBIT
Relevant data have not been disclosed by the company yet.
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Price Momentum
Currency: USD Updated: 2026-02-06The current price momentum score of CASI Pharmaceuticals Inc is 6.06, ranking 133 out of 159 in the Pharmaceuticals industry. Currently, the stock price is trading between the resistance level at 1.13 and the support level at 0.80, making it suitable for range-bound swing trading.
Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Indicators
The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.
This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.
Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.
Moving Average
Indicators
Value
Direction
MA5
0.959
Sell
MA10
0.982
Sell
MA20
1.000
Sell
MA50
0.931
Sell
MA100
1.252
Sell
MA200
1.523
Sell
Institutional Confidence
Currency: USD Updated: 2026-02-06The current institutional shareholding score of CASI Pharmaceuticals Inc is 3.00, ranking 93 out of 159 in the Pharmaceuticals industry. The latest institutional shareholding proportion is 15.33%, representing a quarter-over-quarter decrease of 1.03%. The largest institutional shareholder is James Simons, holding a total of 43.90K shares, representing 0.21% of shares outstanding, with 14.93% decrease in holdings.
Score
Institutional Shareholding
Relevant data have not been disclosed by the company yet.
Risk Assessment
Currency: USD Updated: 2026-02-06The U.S. Dollar Index is currently in a neutral state, which has a neutral effect on the Pharmaceuticals domestic-focused industry. The Dollar Index (DXY) measures the value of the U.S. dollar against a basket of major currencies, including the euro, yen, pound sterling, Canadian dollar, Swedish krona, and Swiss franc. The current risk assessment score of CASI Pharmaceuticals Inc is 2.11, ranking 137 out of 159 in the Pharmaceuticals industry. The company's beta value is 0.90. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets. CASI Pharmaceuticals Inc’s latest ESG disclosure leads the Pharmaceuticals industry, indicating outstanding, compliant performance across environmental management, social responsibility, and governance, which may help mitigate overall risk.
Score
Beta vs S&P 500 index
0.90
VaR
+8.33%
240-Day Maximum Drawdown
+69.51%
240-Day Volatility
+136.57%
Return
Best Daily Return
60 days
+23.26%
120 days
+26.72%
5 years
+51.16%
Worst Daily Return
60 days
-10.62%
120 days
-13.30%
5 years
-28.89%
Sharpe Ratio
60 days
-1.27
120 days
-1.00
5 years
-0.19
Risk Assessment
Maximum Drawdown
240 days
+69.51%
3 years
+90.41%
5 years
+96.10%
Return-to-Drawdown Ratio
240 days
-0.89
3 years
-0.16
5 years
-0.20
Skewness
240 days
+2.27
3 years
+1.63
5 years
+1.43
Volatility
Realised Volatility
240 days
+136.57%
5 years
+116.87%
Standardised True Range
240 days
+17.92%
5 years
+42.80%
Downside Risk-Adjusted Return
120 days
-222.17%
240 days
-222.17%
Maximum Daily Upside Volatility
60 days
+71.93%
Maximum Daily Downside Volatility
60 days
+51.06%
Liquidity
Average Turnover Rate
60 days
+9.44%
120 days
+4.79%
5 years
--
Turnover Deviation
20 days
+1246.40%
60 days
+414.69%
120 days
+161.17%
Peer Comparison
Pharmaceuticals
CASI Pharmaceuticals Inc
CASI
6.44 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Mckesson Corp
MCK
9.07 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Gilead Sciences Inc
GILD
8.92 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
United Therapeutics Corp
UTHR
8.86 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Regeneron Pharmaceuticals Inc
REGN
8.72 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Mirum Pharmaceuticals Inc
MIRM
8.70 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
View more
